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In Brief
Dobie et al. use scRNA-seq to reveal
spatial and functional zonation of hepatic
stellate cells (HSCs) across the hepatic
lobule, identifying central vein-
associated HSCs as the dominant
pathogenic collagen-producing cells
during centrilobular injury-induced
fibrosis. This illustrates the power of
scRNA-seq to resolve the key collagen-
producing cells driving liver fibrosis.
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Iterative liver injury results in progressive fibrosis dis-
rupting hepatic architecture, regeneration potential,
and liver function. Hepatic stellate cells (HSCs) are
a major source of pathological matrix during fibrosis
and are thought to be a functionally homogeneous
population. Here, we use single-cell RNA sequencing
to deconvolve the hepatic mesenchyme in healthy
and fibrotic mouse liver, revealing spatial zonation
of HSCs across the hepatic lobule. Furthermore, we
show that HSCs partition into topographically dia-
metric lobule regions, designated portal vein-associ-
ated HSCs (PaHSCs) and central vein-associated
HSCs (CaHSCs). Importantly we uncover functional
zonation, identifying CaHSCs as the dominant path-
ogenic collagen-producing cells in a mouse model
of centrilobular fibrosis. Finally, we identify LPAR1
as a therapeutic target on collagen-producing
CaHSCs, demonstrating that blockade of LPAR1 in-
hibits liver fibrosis in a rodent NASH model. Taken
together, our work illustrates the power of single-
cell transcriptomics to resolve the key collagen-pro-
ducing cells driving liver fibrosis with high precision.
INTRODUCTION
Liver cirrhosis is a major global healthcare burden, with an esti-
mated 844 million people suffering from chronic liver disease1832 Cell Reports 29, 1832–1847, November 12, 2019 ª 2019 The A
This is an open access article under the CC BY license (http://creativeworldwide (Marcellin and Kutala, 2018). Mortality rates second-
ary to liver cirrhosis continue to increase, with no Food and
Drug Administration (FDA)- or European Medicines Agency
(EMA)-approved antifibrotic treatments currently available, and
liver transplantation only accessible to a select few (Friedman
et al., 2018; Koyama et al., 2016; Tapper and Parikh, 2018).
An ideal antifibrotic therapy would specifically target the patho-
genic collagen-producing cell population without perturbing
homeostatic mesenchymal function. Therefore, increasing our
understanding of the precise cellular andmolecular mechanisms
regulating liver fibrosis is fundamental to the rational design and
development of effective, highly targeted anti-fibrotic therapies
for patients with chronic liver disease (Ramachandran and Hen-
derson, 2016; Trautwein et al., 2015).
Myofibroblasts are the key source of pathogenic extracellular
matrix deposition during hepatic fibrogenesis and therefore have
attracted considerable interest as a potential therapeutic target
(Dobie and Henderson, 2016; Friedman, 2015; Hinz et al.,
2012; Kisseleva, 2017). Although different mesenchymal cell
types have been proposed as the predominant source of myofi-
broblasts following liver injury (Iwaisako et al., 2014; Kisseleva
et al., 2006; Li et al., 2013; Mederacke et al., 2013), recent
studies suggest that hepatic stellate cells (HSCs), first described
by Kupffer in 1876 as vitamin A+ lipid droplet-containing cells
that reside in the perisinusoidal space of the liver (Wake, 1971),
are the dominant contributors to the myofibroblast pool inde-
pendent of the etiology of liver fibrosis (Iwaisako et al., 2014; Me-
deracke et al., 2013). Furthermore, since the discovery 35 years
ago that HSCs are major collagen-producing cells in the liver
(Friedman et al., 1985; de Leeuw et al., 1984), these cells have
been regarded as a functionally homogeneous population, withuthor(s).
commons.org/licenses/by/4.0/).
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Figure 1. Deconvolution of the Mouse Hepatic Mesenchyme Identifies Three Distinct Subpopulations in Liver Homeostasis
(A) Overview: representative immunofluorescence image depicts GFP reporting in the liver of healthy Pdgfrb-BAC-eGFP reporter mice. Scale bar, 100 mm; portal
vein (*) as indicated. CV, central vein; PV, portal vein. GFP+ cells were processed for droplet- and plate-based scRNA-seq.
(legend continued on next page)
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the potential to transition to the activated, collagen-secreting
myofibroblast phenotype thought to be equally distributed
across all HSCs.
Single-cell RNA sequencing (scRNA-seq) is transforming our
understanding of disease pathogenesis (Lee et al., 2017; Stub-
bington et al., 2017; Zepp et al., 2017). Here, we use scRNA-
seq to resolve the hepatic mesenchyme in an unbiased manner
at high resolution, analyzing the transcriptomes of over 30,000
hepatic mesenchymal cells. Our data: (1) deconvolve the hepatic
mesenchyme in healthy and fibroticmouse liver; (2) reveal spatial
zonation of HSCs across the hepatic lobule; (3) generate gene
signatures and markers that partition HSCs into two topograph-
ically diametric lobule regions, namely portal vein-associated
HSCs (PaHSCs) and central vein-associated HSCs (CaHSCs);
(4) importantly, uncover functional zonation of HSCs, identifying
that CaHSCs, but not PaHSCs, are the dominant pathogenic
collagen-producing cells in a mouse model of centrilobular
liver injury; and (5) identify LPAR1 as a therapeutic target on
collagen-producing HSCs and demonstrate that pharmacolog-
ical antagonism of LPAR1 inhibits liver fibrosis. These studies
allow us to further define and resolve the spatial, cellular, and
molecular complexity present within the hepatic fibrotic niche.
Our work highlights the power of scRNA-seq in identifying the
key collagen-producing cells driving centrilobular liver fibrosis
with high precision and therefore should serve as a framework
for the high-resolution identification of the critical pathogenic
cells and related therapeutic targets in a broad range of fibrotic
diseases.
RESULTS
Deconvolution of the Mouse Hepatic Mesenchyme
Identifies Three Distinct Subpopulations in Liver
Homeostasis
We used a Pdgfrb-GFP knockin reporter mouse to label all
mesenchymal cells in the mouse liver (Figure 1A). This reporter
strain has previously been shown to label all mesenchymal cells
(including HSCs) (Henderson et al., 2013). Here, we show that
the Pdgfrb-GFP mouse labeled PDGFRb+ cells in liver with
high efficiency and specificity (Figure S1A). Two independent
digestion protocols and gating strategies were used to isolate
the different GFP+ mesenchymal cell populations (Figure S1B;
STAR Methods). To initially characterize the hepatic mesen-
chyme at single-cell resolution, we used the 10X Chromium
protocol to sequence 12,533 cells from mice (n = 3 digestion
protocol 1; n = 3 digestion protocol 2) at a mean read depth of
85 K reads per cell, which show negligible endothelial, epithe-
lial, and leucocyte contamination (Figures 1A, S1C, and S1D).(B) t-Distributed stochastic neighbor embedding (t-SNE) visualization: 12,533 m
subpopulations. Selected marker genes are listed alongside each cluster.
(C) Representative immunofluorescence images of healthymurine livers: CD34/Re
vein (*) and central vein (#) as indicated. Yellow arrow indicates CD34+ fibroblast
(D) Schematic representation of the topography of the three identified mesenchy
artery; BD, bile duct.
(E) Representative immunofluorescence images of healthy human livers: MFAP4/R
(*) as indicated.
(F) GO enrichment terms associated with signatures A–C corresponding to the th
See also Figures S1, S2, and S3.
1834 Cell Reports 29, 1832–1847, November 12, 2019We identified three subpopulations of mesenchymal
(PDGFRb+) cells (Figure 1B) with distinct sets of marker genes
(Figure S2A; Table S1). Identifying highly specific marker
genes (Figure S2B) and performing immunofluorescence co-
staining (Figure 1C) validated the three mesenchymal subpop-
ulations and delineated their topography. We found that CD34+
PDGFRb+ cells reside primarily in the portal niche, adjacent to
PanCK+ biliary epithelial cells, with rare cells also found around
the central vein, possibly representing second layer cells (Fig-
ure S2C) (Bhunchet and Wake, 1992). Reelin+ PDGFRb+ cells
were found in the perisinusoidal space throughout the paren-
chyma (Figure S2D). Calponin 1+ PDGFRb+ cells were located
within both the hepatic artery and the portal vein walls (Fig-
ure S2E). Given the topographic distribution of these three
mesenchymal subpopulations, we labeled them as fibroblasts
(FBs), HSCs, and vascular smooth muscle cells (VSMCs),
respectively (Figure 1D). We annotated the CD34+ mesen-
chymal subpopulation as FBs, which are known to be
major mediators of matrix turnover in the portal niche (Wells,
2014). The Reelin+ subpopulation represents HSCs, located
throughout the parenchyma, with functions including vitamin
A storage and antigen presentation (Friedman, 2008; Winau
et al., 2007). Finally, the topography of the Calponin 1+ subpop-
ulation is consistent with a VSMC phenotype (Patel et al.,
2016).
To determine whether similar mesenchymal subpopulations
exist in healthy human liver, we performed immunofluorescence
co-staining using genes identified asmarkers in themouse data-
set (Figure 1E). Akin to our findings in mouse liver, we identified
three topographically distinct mesenchymal subpopulations.
MFAP4+ PDGFRb+ cells were confined to the portal niche,
consistent with the CD34+ PDGFRb+ subpopulation observed
in the portal niche of mouse liver. RGS5+ PDGFRb+ cells were
found in locations throughout the hepatic parenchyma, consis-
tent with HSCs. MYH11+ PDGFRb+ cells were located around
portal vein walls, consistent with VSMCs.
To assess the functional profile of the three mouse mesen-
chymal subpopulations, we generated self-organizing maps
using the SCRAT R package (Camp et al., 2017) to visualize
coordinately expressed gene groups across the transcrip-
tomic landscape (Figure S2F). We identified three metagene
signatures, denoted as A–C, that strongly define the subpop-
ulations (Table S2). Signature A, enriched for gene ontology
(GO) terms relating to extracellular structure organization,
defined both FBs and VSMCs mesenchymal subpopulations.
Signature B defined the HSCs subpopulation and was en-
riched for terms including retinoid metabolic process and
antigen processing and presentation. Signature C definedesenchymal cells (median nGene = 2,268, nUMI = 5,725) cluster into three
elin/Calponin 1 (red), PDGFRb (green), PanCK (white). Scale bar, 100 mm; portal
s.
mal subpopulations in the liver. CV, central vein; PV, portal vein; HA, hepatic
GS5/MYH11 (red), PDGFRb (green), DAPI (blue). Scale bar, 100 mm; portal vein
ree identified mesenchymal subpopulations.
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VSMCs exclusively and was enriched for terms such as actin
filament-based processes (Figures 1F and S2F).
Using a single-cell approach also allowed us to interrogate
‘‘traditional’’ hepatic mesenchymal markers at high resolution.
We found that certain historic HSC markers, such as Des and
Vim, were expressed variably across all three mesenchymal
subpopulations (Figure S2G). In keeping with recent findings
(Mederacke et al., 2013), Gfap expression was negligible in our
dataset. We confirmed Lrat and Reln as specific markers for
HSCs within the hepatic mesenchyme (Lua et al., 2016; Meder-
acke et al., 2013), and Ngfr displayed a spectrum of expression
across the HSC population. Pdgfra expression was confined to
the FB and HSC subpopulations as opposed to Pdgfrb, which
was pan-mesenchymal.
To reproduce our 10X Chromium-based findings, and to
assess whether a plate-based full-length transcript approach
would identify similar mesenchymal subpopulations, we also
obtained scRNA-seq data of PDGFRb+ cells in liver using
SmartSeq2 (SSeq2). We sequenced 905 cells isolated using
both digestion protocols at a mean read depth of 456 K reads
per cell. Analysis of this SSeq2 dataset identified the same
three mesenchymal subpopulations (Figure S3A; Table S1)
with negligible non-mesenchymal cell contamination (Fig-
ure S3B). This alternative sequencing approach replicated our
findings both in terms of the marker genes identified previously
and the GO profiles generated using SCRAT (Figures S3C–
S3G; Table S2).
Uncovering HSC Zonation across the Healthy Liver
Lobule
The micro-architecture of the hepatic lobule displays highly or-
dered three-dimensional structural motifs consisting of a portal
triad, hepatocytes arranged in linear cords between a sinusoidal
capillary network, and a central vein and is highly conserved
across species (Burke et al., 2009; Gebhardt, 1992; Kietzmann,
2017). Given the known zonation of hepatocytes (Halpern
et al., 2017; Lamers et al., 1989) and endothelia (Halpern et al.,
2018) across the liver lobule, and having observed variable
patterns of gene expression in the HSC population (Figure S2G),
we investigated the existence of similar zonation in HSCs. We
used independent component analysis (ICA) to identify a set of
highly variable genes in uninjured HSCs (Figure 2A). Threshold-
ing on the gene weight loadings along this component, we ex-
tracted 81 genes consisting of two opposed signatures: 52
genes associated with and including Ngfr and Itgb3 and 29Figure 2. Uncovering HSC Zonation across the Healthy Liver Lobule
(A) Heatmap of relative expression (center): cubic smoothing spline curves fitted
ordered on their contribution to IC2, with top-most genes displaying the stronge
Zonation profiles for exemplar genes shown left and right.
(B) Representative immunofluorescence and RNAscope images of healthy murin
(blue). Scale bar, 100 mm. Yellow arrows indicate Adamtsl2+ cells. ICA visualizatio
components of the HSC subpopulation in homeostatic murine liver. Bar plots (be
portal and peri-central regions; error bars SEM, Mann-Whitney test, *p < 0.05.
(C) Schematic representation of the topography of the twoHSC subpopulations in
duct.
(D) Representative immunofluorescence images of healthy human livers: NGFR/A
bar, 100 mm; portal vein (*) and central vein (#) as indicated. Yellow dashed lines
See also Figures S4 and S5.
1836 Cell Reports 29, 1832–1847, November 12, 2019genes associated with and including Adamtsl2 and Rspo3
(Figure 2A; Table S1). Supervised clustering using this signa-
ture allowed us to separate the HSCs into two further
subpopulations.
To determine the topography of these subpopulations, we
selected marker genes using the following criteria: (1) high
gene weight loading on the independent component (IC) (Fig-
ure 2A), (2) mesenchyme specificity (Figure S4A), and (3) within
the mesenchyme, greatest specificity to HSCs (Figure S4B).
We identified Adamtsl2 and Ngfr as the best candidate markers.
Using a combination of a highly sensitive modified in situ RNA
hybridization procedure (RNAscope) and immunofluorescence
staining, we confirmed Adamtsl2 and NGFR to be mesenchymal
markers each labeling a subpopulation of HSCs (Figure S4A). To
explore how this topography related to zonally distributed hepa-
tocytes, we co-stained with peri-portal (E-cadherin) and peri-
central (Cyp2e1) hepatocyte markers (Doi et al., 2007; Rocha
et al., 2015). We found NGFRhi HSCs located in the same region
of the liver lobule as portal vein-associated (E-cadherin+) hepa-
tocytes, whereas Adamtsl2hi HSC was located in the same re-
gion of the liver lobule as central vein-associated hepatocytes
(Cyp2e1+) (Figures 2B and S4C). This allowed us to annotate
these two HSC subpopulations as NGFRhi portal vein-associ-
ated HSCs (PaHSCs) and Adamtsl2hi central vein-associated
HSCs (CaHSCs) (Figure 2C).
To determine whether healthy human liver exhibits similar
HSC zonation, we performed immunofluorescence co-staining
using marker genes orthologous to those that delineated mouse
HSC zonation—Ngfr and Adamtsl2—with the previously identi-
fied HSC marker RGS5 (Figure S4D). Akin to our findings in
mouse liver, we observed zonal expression of NGFR and
ADAMTSL2 across the human liver lobule (Figure 2D).
Certain genes within our zonation signature, such as Itgb3 and
Rspo3, have previously been identified as landmark genes used
to zonally define endothelial cells across the liver lobule (Halpern
et al., 2018). Spatial mapping of these populations using RNA-
scope and immunofluorescence staining confirmed the pres-
ence of zonally distributed ITGB3+ (Integrin b3) and Rspo3+
HSCs within the parenchyma (Figure S5A). In line with previous
studies, Integrin b3hi HSCs were observed in the peri-portal re-
gion and Rspo3hi HSCs in the peri-central region, suggesting
possible spatial correlation between the endothelial and mesen-
chymal lineages (Figures S5A and S5B). Immunofluorescence
staining of PaHSC marker NGFR and previously identified cen-
tral-associated endothelial cell marker thrombomodulin (Halpernto markers of HSC zonation and plotted along IC2; genes are thresholded and
st negative correlation with bottom-most genes. Cells columns, genes rows.
e livers: NGFR/Adamtsl2 (RNAscope) (red), E-cadherin/Cyp2e1 (green), DAPI
ns (below): Ngfr and Adamtsl2 expression on the first and second independent
low): number of PaHSCs (left; n = 4) and CaHSCs (right; n = 4) per mm2 in peri-
healthy liver lobule. CV, central vein; PV, portal vein; HA, hepatic artery; BD, bile
DAMTSL2 (red), CK19 (biliary epithelial cell marker; green), DAPI (blue). Scale
mark areas of low/neg marker staining.
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et al., 2018) further demonstrated zonation, with each marker
defining a distinct region within the hepatic lobule (Figure S5C).
HSC Populate the Fibrotic Niche in a Mouse Model of
Centrilobular Fibrotic Liver Injury
Chronic carbon tetrachloride (CCl4) administration is a broadly
utilized, highly reproducible, and robust mouse model of centri-
lobular liver fibrosis that recapitulates many of the features of
human fibrotic liver disease (Figures S6A and S6B). To investi-
gate mesenchymal cell heterogeneity in fibrotic mouse liver,
we sequenced 10,758 Pdgfrb-GFP+ reporter cells from murine
liver following 6 weeks CCl4 administration using the 10X Chro-
mium workflow and performed unsupervised clustering along-
side our homeostatic hepatic mesenchyme dataset (Figures
S6C and S6D).
We observed the same three mesenchymal subpopulations in
both healthy and fibrotic livers (Figures 3A and 3B), with previ-
ously identified markers maintaining their specificity following
chronic liver injury (Table S1). Expression of fibrillar collagens
(Col1a1,Col1a2, andCol3a1) remained highest in FBs, however,
a marked increase in expression of Col1a1 was observed in
HSCs following induction of fibrotic injury (Figure 3C). Although
overall marker gene expression profiles remained constant be-
tween uninjured and fibrotic HSCs compared to other mesen-
chymal populations, we also observed decreased expression
of certain marker genes including Reln in HSC overexpressing
fibrillar collagen (Figure S6E). Immunofluorescence staining
confirmed diminished Reelin positivity within the fibrotic niche
(Figure S6F). In contrast, staining for Lhx2 (a mesenchyme-spe-
cific marker of HSCs in both uninjured and 6 weeks CCl4 liver)
confirmed an expansion of HSCs within the fibrotic niche (Fig-
ures 3D, S6F, and S6G). Previous studies have shown that
HSCs are the major source of pathogenic collagen-producing
cells following liver injury (Iwaisako et al., 2014; Mederacke
et al., 2013); in accordance we did not identify FBs and VSMCs
within the fibrotic niche, as evidenced by immunofluorescence
staining for markers MFAP4 and Calponin 1 (Figure 3E). We
observed minimal proliferation across all three populations
(2.4% of mesenchymal cells in the dataset expressed prolifera-
tion marker Mki67), confirmed by ethynyldeoxyuridine (EdU)
staining in CCl4-treated livers (2.6% of mesenchymal cells;
Figure 3F).Figure 3. HSCs Populate the Fibrotic Niche in a Mouse Model of Centr
(A) t-SNE visualization: 23,291mesenchymal cells (median nGene = 2,339, nUMI =
subpopulations. FB, fibroblasts; HSC, hepatic stellate cells; VSMC, vascular sm
(B) t-SNE visualizations: cells from uninjured (gray) and fibrotic (pink) livers.
(C) Violin plots: expression of fibrillar collagen genes (Col1a1,Col1a2, and Col3a1
bar indicates median. Mann-Whitney test, ****p value < 0.0001.
(D) Representative immunofluorescence images of fibrotic murine liver and qua
collagen 1 (white), PDGFRb (green), DAPI (blue). Scale bar, 100 mm. Yellow dashe
cells per mm2 in uninjured (n = 4) and fibrotic (n = 4) liver; error bars SEM, Mann
(E) Violin plots (top): expression of mesenchymal cell subpopulation markers.
MFAP4/Lhx2/Calponin 1 (red), collagen 1 (green), DAPI (blue). Scale bar, 100 mm
indicate Lhx2+ cells within the fibrotic niche.
(F) Violin plot (top): expression of proliferation marker Mki67 across the three m
fibroticmurine liver (middle): EdU (red), PDGFRb (green), DAPI (blue). Scale bar, 10
SEM. Yellow arrow indicates proliferating PDGFRb+ cell.
See also Figure S6.
1838 Cell Reports 29, 1832–1847, November 12, 2019CaHSCs Are the Dominant Pathogenic Collagen-
Producing Cells in a Mouse Model of Centrilobular
Fibrotic Liver Injury
Since the discovery 35 years ago that HSCs are major
collagen-producing cells in the liver (Friedman et al., 1985; de
Leeuw et al., 1984), they have been regarded as a functionally
homogeneous population, with the potential to transition to the
activated, collagen-secreting myofibroblast phenotype thought
to be equally distributed across all HSCs. Having identified
HSC zonation in the homeostatic liver, we therefore investi-
gated the relative contributions of PaHSCs and CaHSCs to
the fibrotic process. We performed supervised clustering on
the combined healthy and fibrotic HSC populations based on
their expression of the 81 zonation genes previously identified
in homeostatic HSCs (Table S1) and found clear conservation
of the zonation genes observed in homeostasis: 51/52
PaHSC-associated genes including Ngfr and Itgb3 and 26/29
CaHSC-associated genes including Adamtsl2 and Rspo3
continued to define the zonation profile of the combined
HSCs cluster (Figure 4A). This again allowed delineation of
HSCs into PaHSC and CaHSC subpopulations (Figure 4B).
To investigate whether our zonation signature correlated with
pathogenic collagen-producing HSCs, we created a myofibro-
blast signature by thresholding HSCs on fibrillar collagen
(Col1a1, Col1a2, and Col3a1) overexpression, a hallmark of
HSC activation. This signature was then mapped onto our
zonation profile to identify the contribution of PaHSCs and
CaHSCs to the pathogenic myofibroblasts. In this way, we iden-
tify CaHSCs as the dominant pathogenic collagen-producing
HSCs, representing 88% of myofibroblasts classified in this
manner (Figure 4C). These findings were validated by spatial
mapping of CaHSCs and PaHSCs in fibrotic liver using RNA-
scope and immunofluorescence staining. Adamtsl2hi CaHSCs
were located throughout the fibrotic niche whereas NGFRhi
PaHSCs resided predominately in the parenchyma distal to the
fibrotic region. (Figures 4D and S7A). A similar difference in
topography was observed with other zonation markers Rspo3
and Integrin b3 (Figure S7B).
To further investigate the contribution of CaHSCs to patho-
genic collagen production during fibrosis, we used self-orga-
nizing maps to identify metagene signatures enriched in the
collagen-producing HSCs (Figure S7C; Table S2). Signature Ailobular Fibrotic Liver Injury
6,081) from uninjured and fibrotic (6 weeksCCl4) mouse livers cluster into three
ooth muscle cells. Selected marker genes listed alongside each cluster.
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ntification of Lhx2+ HSC in fibrotic versus uninjured murine liver: Lhx2 (red),
d line marks magnified area (scale bar, 20 mm). Bar plot (right): number of Lhx2+
-Whitney test, *p value < 0.05.
Representative immunofluorescence images of fibrotic murine liver (below):
. Yellow dashed line marks magnified area (scale bar, 20 mm). Yellow arrows
esenchymal subpopulations. Representative immunofluorescence images of
0 mm. Bar plot (bottom): percentage EdU+mesenchymal cells (n = 3); error bars
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was expressed across both PaHSCs and CaHSCs, with en-
riched GO terms such as retinoid metabolic process that also
defined uninjured HSCs (Figure 1F). Signature B was highly en-
riched for terms related to collagen production, and all HSCs
that expressed signature B were CaHSCs.
Having identified CaHSCs as the predominant pathogenic
collagen-producing HSCs, we used the monocle R package to
further investigate changes in gene expression within the
CaHSCs. This highlighted the transition from a quiescent to a
collagen-producing phenotype, with upregulation following injury
of pro-fibrogenic genes including Col1a1, Col1a2, Col3a1, and
Lox, with associated enriched GO terms such as extracellular
structure organization and collagen fibril organization, and
downregulation of uninjured HSC-related genes including
Ecm1, Reln, Hgf, and Rgs5 (Figures 4E and 4F; Table S3).
CaHSCs Are the Dominant Pathogenic Collagen-
Producing Cells following Acute Centrilobular Liver
Injury
Acute CCl4-induced liver injury is characterized by significant
HSC proliferation (14.4% of Lhx2+ HSCs) and activation to a
collagen-producing myofibroblast phenotype in the centrilobular
region (Figures S8A–S8C). To further interrogate the dynamics
of PaHSC and CaHSC differentiation into pathogenic collagen-
producing cells, we sequenced 7,260 HSCs from Pdgfrb-GFP
reporter mice following acute CCl4-induced liver injury (Figures
S8D and S8E).
We used the 81 zonation genes identified in homeostatic
HSCs to classify these cells into PaHSC and CaHSC subpopula-
tions (Figures 5A and S8F). Both subpopulations contained cells
expressing the known proliferation markerMki67, however, only
CaHSCs showed elevated levels of known genes associated
with fibrogenesis (Figures 5B and 5C). Spatial mapping of these
subpopulations using RNAscope combined with immunofluo-
rescence staining confirmed the pathogenic collagen-producing
cells in the fibrotic niche as overwhelmingly Adamtsl2hi CaHSCs
(Figures 5D and S8G).
CaHSCs, but Not PaHSCs, Differentiate into Pathogenic
Collagen-Producing Cells following Acute Centrilobular
Liver Injury
We used the velocyto R package (La Manno et al., 2018) to inter-
rogate the HSC injury response by calculating cellular velocityFigure 4. CaHSCs Are the Dominant Pathogenic Collagen-Producing C
(A) Heatmap of relative expression: cubic smoothing spline curves fitted to previou
associated (portal vein-associated) signature and annotated by cell condition. C
(B) t-SNE visualizations: clustering HSCs from uninjured and fibrotic (6 weeks CC
clusters.
(C) t-SNE visualizations: thresholding HSCs on expression of fibrillar collagen g
qPaHSCs (blue) and qCaHSCs (red), HSCs below fibrillar collagen threshold, wher
threshold. Bar plot (right): cell counts for PaHSCs versus CaHSCs from fibrotic li
(D) Representative immunofluorescence and RNAscope images of fibrotic livers
Scale bar, 20 mm. Yellow dashed line marks area of NGFRlo/neg HSCs.
(E) Heatmap of relative expression: cubic smoothing spline curves fitted to gen
broblast, grouped by hierarchical clustering (k = 3). Gene co-expression module
(F) Cubic smoothing spline curves fitted to averaged relative expression of all ge
ofibroblast; selected GO enrichment terms for module 2 (bottom).
See also Figure S7.
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likelihood of transition between CaHSCs and PaHSCs was negli-
gible, thus inferring absence of pseudotemporal dynamics be-
tween the two subpopulations (Figure S9A). Furthermore, fibro-
genic genes such as Col1a1, Col3a1, and Acta2 display
positive residuals (unspliced/spliced mRNA ratio) for CaHSCs
but not for PaHSCs, reinforcing their potential for myofibroblast
transition (Figure S9B). This demonstrated that HSC differentia-
tion into pathogenic collagen-producing cells occurred in
CaHSCs, but not in PaHSCs (Figure 6A). We thus used the
monocle R package to independently define trajectories for
CaHSCs and PaHSCs (Figure 6B). CaHSCs exhibited a branch-
ing trajectory (Figure 6B), with one branch transitioning from
quiescence into a collagen-producing phenotype with upregula-
tion of pro-fibrogenic genes including Col1a1, Col1a2, Col3a1,
and Acta2, and the other branch displaying a primarily prolifera-
tive response (Figures 6B–6D; Table S3). PaHSCs displayed a
proliferative response but did not transition to collagen-produc-
ing cells (Figures 6B, 6E, and 6F; Table S3). Immunofluorescence
co-staining verified similar levels of proliferation between
PaHSCs and CaHSCs following acute CCl4-induced liver injury
(Figure 6G).
Having identified CaHSCs as the pathogenic collagen-pro-
ducing cells, we used the SCENIC R package (Aibar et al.,
2017) to provide mechanistic insight into the transcriptional
regulation of HSC activation following both acute and chronic
CCl4-induced liver injury. SCENIC identifies sets of genes that
co-express with known transcription factors and are differen-
tially expressed along the CaHSC activation trajectories. We
observed 50 such regulons in the acute activation trajectory
and 29 in the chronic trajectory of which 18 were shared be-
tween both, including Egr2, Sox4, Plagl1, Rxra, Foxf1, and
Klf7 (Mann and Smart, 2002; Vollmann et al., 2017) (Figures
S9C and S9D; Table S3). As both fibroblasts and HSC-derived
myofibroblasts are responsible for collagen deposition, we
were keen to identify unique regulatory elements for the latter.
We identified transcription factors Sox4 and Rxra as specific
to HSCs following chronic CCl4-induced liver injury (Fig-
ure S9E). Again focusing on potential regulatory target genes
conserved between the two injury models, SCENIC uncovers
6 genes associated with Rxra and 5 genes associated with
Sox4 (Figure S9F). Genes associated with the Sox4 regulon
include Mdk and Hmcn1 that have previously been shown toells in a Mouse Model of Centrilobular Fibrotic Liver Injury
sly definedmarkers of zonation inmurine HSCs, ordered by expression ofNgfr-
ells columns, genes rows.
l4) livers on zonation signature separates them into distinct PaHSC and CaHSC
enes (Col1a1, Col1a2, and Col3a1), PaHSCs (left) versus CaHSCs (middle).
e q = quiescent HSC state; myofibroblast (green), HSCs above fibrillar collagen
vers. Green portion of bars represent HSCs above fibrillar collagen threshold.
: Adamtsl2 (RNAscope)/NGFR (red), collagen 1/PDGFRb (green), DAPI (blue).
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See also Figure S8.have important roles in fibrosis in other organs (Chowdhury
et al., 2014; Misa et al., 2017).
Targeting of LPAR1 on Collagen-Producing HSCs
Inhibits Liver Fibrosis
The Lpar1 gene encodes lysophosphatidic acid receptor 1
(LPAR1), a G protein-coupled receptor that binds the lipid
signaling molecule lysophosphatidic acid (LPA). Previous
studies have shown LPAR1 expression to be restricted to
non-parenchymal cells and elevated in activated HSCs, with
minimal expression reported in other hepatic lineages,
including hepatocytes (Nakagawa et al., 2016; Simo et al.,
2014). Having identified CaHSC as the predominant pathogenic
collagen-producing cell during CCl4-induced centrilobular
murine liver fibrosis, we identified that Lpar1 was expressedin CaHSC but not PaHSC following acute and chronic CCl4-in-
duced liver injury (Figure 7A). Lpar1 was not expressed in
hepatic leucocytes and endothelial cells following chronic
CCl4-induced liver injury (Figure 7B).
To investigate whether LPAR1 is expressed on pathogenic
collagen-producing cells in human liver cirrhosis, we interro-
gated the hepatic mesenchyme at single-cell resolution in a pre-
viously published dataset (Figure 7C) (Ramachandran et al.,
2019). Unsupervised clustering identified three mesenchymal
subpopulations, including a subpopulation which expands in
cirrhosis and is defined by upregulation of fibrillar collagen
expression, referred to as myofibroblasts (Figures 7C and 7D).
Akin to our observations in murine liver injury, LPAR1 expression
was restricted to the collagen-producing subpopulation
(Figure 7D).Cell Reports 29, 1832–1847, November 12, 2019 1841
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Previous studies have revealed a role for LPA signaling in HSC
activation (Yanase et al., 2000), and LPAR1 antagonism has
been shown to reduce fibrosis in a rodent model of hepatocellu-
lar carcinoma andmousemodel of centrilobular fibrosis (Bollong
et al., 2017; Nakagawa et al., 2016). As proof-of-concept of our
scRNA-seq approach, we investigated the effects of LPAR1
antagonism on human HSC contractility and activation in vitro.
LPA, a known ligand of LPAR1, is amajor driver of actin polymer-
ization and actomyosin contraction in HSCs (Yanase et al.,
2000); LPAR1 antagonism inhibited LPA-induced HSC contrac-
tility, pro-fibrogenic connective tissue growth factor (CTGF)
expression, F-actin polymerization, and phosphorylation of
myosin light chain 2 (Figure S10).
The prevalence of non-alcoholic steatohepatitis (NASH) as a
leading cause of chronic liver disease has reached epidemic
proportions (Friedman et al., 2018). To assess whether LPAR1
expression increases during the evolution of human NASH-
induced liver fibrosis, we performed bulk RNA-seq of human liver
samples from a cohort of biopsy-confirmed NASH patients with
a range of fibrosis stages (F1–F4). LPAR1 expression increased
with fibrosis stage (Figure 7E) and correlated with fibrillar
collagen expression (Figure 7F). To further assess whether
LPAR1 antagonism inhibits liver fibrosis in vivo, we used a 12-
week choline-deficient high-fat diet (CDHFD) rodent model of
NASH. LPAR1 antagonism markedly reduced liver fibrosis as
measured by digital morphometry of picrosirius red and aSMA
(Figure 7G) and hydroxyproline assay (Figure 7H).
DISCUSSION
Despite significant advances in our understanding of the cellular
and molecular mechanisms driving liver fibrosis over the past 40
years, there are still no FDA- or EMA-approved antifibrotic treat-
ments currently available. Therefore, there remains a clear
imperative to further resolve and understand the complex
mechanisms that regulate the fibrotic niche, both in the liver
and other organs.
scRNA-seq has facilitated the interrogation of mesenchymal
heterogeneity at unprecedented resolution and has greatly
advanced our understanding of mesenchymal cell biology and
function in disease pathogenesis across various tissues (Croft
et al., 2019; Guerrero-Juarez et al., 2019; Peyser et al., 2019;Figure 6. CaHSCs, but Not PaHSCs, Differentiate into Pathogenic Coll
(A) t-SNE visualization: RNA velocity field (black vectors) visualized using Gauss
(B) Annotating pseudotemporal dynamics (purple to yellow) on PaHSC (left) and
(C) Heatmap of relative expression: cubic smoothing spline curves fitted to genes
arrow) and across quiescent to proliferating CaHSC (left arrow) pseudotempora
modules labeled right.
(D) Cubic smoothing spline curves fitted to averaged expression of all genes in
jectory, selected GO enrichment terms (right), and module 2 (bottom) along th
enrichment terms (right).
(E) Heatmap of relative expression: cubic smoothing spline curves fitted to gen
temporal trajectory, grouped by hierarchical clustering (k = 2). Gene co-expressi
(F) Cubic smoothing spline curves fitted to averaged expression of all genes in
selected GO enrichment terms (right).
(G) Representative immunofluorescence image of murine liver following acute CCl
(white), DAPI (blue). Scale bar, 100 mm. Bar plot (right): percentage EdU+ PaHSC
See also Figure S9.Xie et al., 2018). Investigating specificmesenchymal populations
in normal and fibrotic liver has been hampered by the lack of
reliable markers required to distinguish these subpopulations
(Wells, 2014). In this study, we use a scRNA-seq approach to
deconvolve for the first time the entire hepatic mesenchyme in
healthy and fibrotic mouse liver, identifying three distinct popula-
tions of mesenchymal cells. Wemake this data freely available to
browse at http://livermesenchyme.hendersonlab.mvm.ed.ac.
uk, where it should serve as a useful reference resource for future
studies of the hepatic mesenchyme.
Multiple mesenchymal cell types have been proposed as the
major source of myofibroblasts following liver injury (Iwaisako
et al., 2014; Kisseleva et al., 2006; Li et al., 2013; Mederacke
et al., 2013), however, recent studies suggest that HSCs are
the predominant contributors to themyofibroblast pool irrespec-
tive of the cause of liver fibrosis (Iwaisako et al., 2014; Meder-
acke et al., 2013). Our data confirm HSCs as the dominant
mesenchymal contributor to pathogenic collagen production in
CCl4-induced centrilobular injury.
Zonation across the homeostatic liver lobule has recently
been characterized in hepatocytes and endothelial cells using
scRNA-seq approaches (Halpern et al., 2017, 2018), however,
zonation of function in the context of a fibrotic injury response
has not previously been documented in the liver. HSC zonation
has previously been described in porcine liver (Wake and Sato,
1993), and a recent scRNA-seq study in mice concluded that
HSCs from healthy liver are a transcriptionally homogeneous
population (Krenkel et al., 2019). Furthermore, since the discov-
ery 35 years ago that HSCs aremajor collagen-producing cells in
the liver (Friedman et al., 1985; de Leeuw et al., 1984), their po-
tential to transition to the activated, collagen-secretingmyofibro-
blast phenotype has been thought to be equally distributed
across the entire population. In this study, we used scRNA-seq
to uncover heterogeneity within the mesenchyme, including
zonation of HSCs across the hepatic lobule. We show that
HSCs partition into two topographically distinct regions, desig-
nated portal vein-associated HSCs (PaHSCs) and central vein-
associated HSCs (CaHSCs).
Importantly, we also uncover zonation of function in HSCs,
with CaHSCs, but not PaHSCs, responsible for the vast majority
of pathogenic fibrillar collagen-production in the CCl4 mouse
model of centrilobular liver injury. The zonal activation ofagen-Producing Cells following Acute Centrilobular Liver Injury
ian smoothing on regular grid, superimposed on PaHSC and CaHSC clusters.
CaHSC (right) clusters. Arrows indicate simplified overall trajectory.
differentially expressed across quiescent CaHSC to myofibroblast (MFB) (right
l trajectories, grouped by hierarchical clustering (k = 3). Gene co-expression
module 1 (top) along quiescent CaHSC to myofibroblast pseudotemporal tra-
e quiescent to proliferating CaHSC pseudotemporal trajectory, selected GO
es differentially expressed across quiescent to proliferating PaHSC pseudo-
on modules labeled right.
module 2 along quiescent to proliferating PaHSC pseudotemporal trajectory,
4-induced liver injury and EdU incorporation: NGFR (red), PDGFRb (green), EdU
s versus EdU+ CaHSCs (n = 3); error bars SEM.
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Figure 7. Targeting of LPAR1 on Collagen-Producing HSCs Inhibits Liver Fibrosis
(A) Violin plots: expression of fibrillar collagen genes (Col1a1, Col1a2, and Col3a1) and Lpar1 in PaHSCs versus CaHSCs following acute (72 h post single CCl4
injection; top) and chronic (6 weeks CCl4; bottom) liver injury.
(B) Violin plot: expression of Lpar1 in hepatic mesenchymal cells (Mes), endothelial cells (Endo), and leucocytes (Leuc) from chronic liver.
(legend continued on next page)
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CaHSCs following induction of CCl4 is likely to be secondary to
the topographical location of injury, with CCl4 causing necrosis
of hepatocytes in the centrilobular region (Tanaka and Miyajima,
2016). It is possible that PaHSCs may represent the major
collagen-producing HSCs in peri-portal injury models, however,
the relative functional roles of PaHSCs and portal fibroblasts in
the context of biliary injury requires further investigation (Wells,
2014).
Together, this study provides a high-resolution examination of
the hepatic fibrotic niche, via a comprehensive analysis and
partitioning of all the hepatic mesenchymal lineages, and inves-
tigation of their relative contributions to the fibrogenic process.
This scRNA-seq approach has clear implications for the rational
development of antifibrotic therapies; facilitating and informing
specific targeting of pathogenic scar-forming cells without
perturbing homeostatic mesenchymal function, which is of
particular importance in patients with chronic liver disease who
may already have very limited hepatic functional reserve.
In an era of precision medicine, where molecular profiling un-
derpins the development of highly targeted therapies, we used
scRNA-seq to resolve the healthy and fibrotic hepatic mesen-
chyme in high-definition. Our work illustrates the power of sin-
gle-cell transcriptomics to identify the key collagen-producing
cells driving liver fibrosis with high precision and should also
serve as a framework for the high-resolution identification of
pathogenic cells and related therapeutic targets in a broad range
of fibrotic diseases.STAR+METHODS
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EXPERIMENTAL MODELS AND SUBJECT DETAILS
Mice
Pdgfrb-BAC-eGFP reporter mice (on a C57BL/6 background) were obtained from C. Betsholtz. For all experiments, the mice used
were 10–16 week old males housed under pathogen–free conditions at the University of Edinburgh. All experiments were performed
in accordance with the UK Home Office Regulations.
Rats
Wistar-Han rats were obtained from Charles River Laboratories (Kingston). Male 12-week-old rats were used for experiments. All rat
experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the National
Research Council (National Academies Press, 2011) and the National Institutes of Health, Office of Laboratory Animal Welfare.
Rat studies were run at Covance Laboratories Inc. Greenfield, Indiana, USA.
Human tissue
Local approval for procuring human liver tissue for immunofluorescence staining was obtained from the NRS BioResource and Tis-
sue Governance Unit (Study Number SR574), following review at the East of Scotland Research Ethics Service (Reference 15/ES/
0094). All subjects provided written informed consent. Healthy background non-lesional liver tissue was obtained intraoperatively
from male and female patients undergoing surgical liver resection for solitary colorectal metastasis at the Hepatobiliary and Pancre-
atic Unit, Department of Clinical Surgery, Royal Infirmary of Edinburgh. Patients with a known history of chronic liver disease,
abnormal liver function tests or those who had received systemic chemotherapy within the last four months were excluded from
this cohort.
Formalin-fixed, paraffin-embedded (FFPE) liver samples used for tissue RNA-seq were obtained from commercial tissue vendors
(Capital Biosciences, Tissue Solutions, and BioIVT); number of samples, n = 95; Gender (Female), n (%), 59 (62%); fibrosis stage,
F1,F2,F3/F4 – 40,31,24; NAS score (mean ± SD), 5.2 ± 0.9; age (means ± SD, years), 52.4 ± 11.5).
Fibrosis Models
Carbon tetrachloride (CCl4) liver injury was induced as described previously (Henderson et al., 2013). For acute CCl4-induced liver
injury, mice were injected i.p with 1ml/g body weight sterile CCl4 in a 1:3 ratio with olive oil (0.25ul/g CCl4) after overnight fast (with
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with 1ml/g body weight CCl4 in a 1:3 ratio with olive oil (0.25ul/g CCl4) twice weekly for 6 weeks; livers were harvested 48 hours post
final injection. To assess proliferation in vivo, mice were injected i.p with 5-ethynyl-20-deoxyuridine (EdU; 50mg/kg; ThermoFisher
Scientific, C10640) 3 hours prior to sacrifice.
Nonalcoholic steatohepatisis (NASH) was induced by feeding choline-deficient high-fat diet (CDHFD; Research Diets, Inc.,
A06071302) or standard chow (LabDiet, 5CR4) to male Wistar-Han rats to induce nonalcoholic steatohepatitis (NASH). Rats were
administered LPAR1 antagonist AM095 (Swaney et al., 2011) (30mg/kg) (DSK Biopharma) or vehicle (25% (v/v) PEG 200,
74.625% (v/v) deionized water, 0.375% (w/v) Methyl Cellulose (A4M grade)) twice-daily (BID) via oral gavage while being fed a
CDHFD for 12 weeks. Rats were group-housed throughout the experiment and water and feed was provided ad libitum.
Primary cells and cell lines
Primary human hepatic stellate cells (hHSC) were isolated from viable male livers by density gradient centrifugation (Samsara Sci-
ences; Cat, #HLSC; Donor ID, HL1500002SC). TWNT4 cells were obtained courtesy of Bryan Fuchs, PhD (Fuchs et al., 2014; Naka-
gawa et al., 2016). TWNT4 cells and hHSCwere cultured in DMEM (4.5mg/mL glucose, 110mg/L sodiumpyruvate, 4mML-glutamine)
with 10% fetal bovine serum (FBS) supplemented with 100units/mL penicillin and 100mg/mL streptomycin (all fromMediatech, Man-
assus, VA). Cells were maintained at 37C in a humidified incubator with 5% CO2 in air.
METHOD DETAILS
Immunofluorescence Staining
Mouse liver was briefly perfused through the inferior vena cava with PBS, then excised. For staining which included intrinsic GFP
reporting, tissue was fixed/frozen. For all other staining, tissue was formalin-fixed paraffin-embedded.
Fixed/frozen sections
Liver was fixed in 4%paraformaldehyde for 2 hours at 4C then immersed in graded sucrose solutions, embedded in OCT and stored
at –80C. 7mm frozen sections were cut and left to air dry for 30 minutes, washed in PBS, then blocked using protein block (GeneTex,
GTX30963) for 30 minutes. Sections were then incubated with antibodies listed in Table S4 overnight at 4C. Following a further PBS
wash sections were incubated with fluorescently conjugated secondary antibodies depending on host species (Alexa Fluor 555 goat
anti-rat; Alexa Fluor 555 goat anti-rabbit; Alexa Fluor 555 donkey anti-mouse; Alexa Fluor 488 goat anti-chicken (Life Technologies,
A21434, Lot. 1722994; A21429, Lot.1937155; A31570, Lot.1850121; A11039; Lot.1869581, respectively). Co-stains were completed
sequentially. Slides were washed further in PBS before DAPI-containing mountant was applied (ThermoFisher Scientific, P36931).
For PDGFRb staining, before blocking, heat-mediated antigen retrieval in pH9 Tris-EDTA (microwave; 2 minutes) was performed.
Slides were washed in PBS, incubated in 3% hydrogen peroxide for 10 minutes and washed again in PBS before proceeding
with the above protocol. Instead of incubating with a fluorescently conjugated secondary antibody sections were washed with
PBS and then incubated with ImmPress HRP Polymer Detection Reagents (rabbit, MP-7401 Vector Laboratories) for 30 minutes
and washed in PBS again. Staining was detected using Cy3 tyramide (Perkin-Elmer, NEL744B001KT) at 1:1000 dilution. Sections
were imaged using a slide scanner (AxioScan.Z1, Zeiss) at 20X magnification. Images were processed using Zen Blue (Zeiss) and
Fiji image software.
Formalin-fixed paraffin-embedded (FFPE) sections:
Liver was fixed in 4% neutral-buffered formalin for 24 hours followed by paraffin-embedding. 5mm sections were cut, dewaxed, re-
hydrated, then incubated in 4% neutral-buffered formalin for 20 minutes. Following heat-mediated antigen retrieval in pH6 sodium
citrate or pH9 Tris-EDTA (microwave; 15minutes), slideswerewashed in PBS and incubated in 3%hydrogen peroxide for 10minutes.
Slides were then washed in PBS, blocked using protein block (GeneTex, GTX30963) for 1 hour at room temperature, and incubated
with primary antibodies. A full list of primary antibodies and conditions are shown in Table S4. Slides were thenwashed in PBS/T (PBS
plus 0.1% Tween 20; Sigma-Aldrich, P1379), incubated with ImmPress HRP Polymer Detection Reagents (depending on species of
primary; rabbit, MP-7401; mouse, MP-6402-15; goat, MP-7405; all Vector Laboratories) for 30 minutes at room temperature, and
washed again with PBS/T. Staining was detected using either Cy3, Cy5, or Fluorescein tyramide (Perkin-Elmer, NEL741B001KT)
at 1:1000 dilution. For multiplex stains slides were then washed in PBS/T followed by a further heat treatment with pH6 sodium citrate
or pH9 Tris-EDTA (15 minutes), washed in PBS, incubated in 3% hydrogen peroxide for 10 minutes, washed in PBS, protein blocked,
and finally incubated with the second primary antibody followed by the ImmPress Polymer and tyramide as before. When required
this sequence was repeated for the third primary antibody. A DAPI-containing mountant was then applied (ThermoFisher Scientific,
P36931). Sections were imaged using a slide scanner (AxioScan.Z1, Zeiss) at 20X magnification. Images were processed using Zen
Blue (Zeiss) and Fiji image software.
aSMA (Biocare CM001 [1A1], Ms mAb, 0.12ug/mL) IHC staining of rat liver was performed using the Biocare Intellipath autostainer
utilizing Biocare Medical reagents. Following deparaffinization, slides were sequentially treated with hydrogen peroxidase for 5 mi-
nutes, citrate-based heat induced (95C) antigen retrieval for 40 minutes, protein block for 10 minutes, primary antibody for 30 mi-
nutes, one-step polymer-HRP conjugated (mouse on rat HRP) secondary antibody for 30 minutes, DAB chromogen for 5 minutes,
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RNAscope
Detection of Adamtsl2, Rspo3, and Col1a1 was performed using the RNAscope Multiplex Fluorescent Reagent Kit v2 (Advanced
Cell Diagnostics (ACD), Cat, 323100) in accordance with the manufacturer’s instructions. Briefly, 5mm liver sections were dewaxed,
incubated with endogenous enzyme block, boiled in pretreatment buffer and treated with protease, followed by target probe hybrid-
ization using the RNAscopeMm-Adamtsl2-No-XHs (Cat, 465521; Lot, 19086B; ACD), Mm-Rspo3 (Cat, 402011; Lot, 18338A; ACD)
or Mm-Col1a1-C2 (Cat, 31937-C2; Lot, 19086C; ACD) probes. Target RNA was detected with Cy3 (Adamtsl2 or Rspo3) or Fluores-
cein (Col1a1) tyramide (Perkin-Elmer) at 1:750 dilution. For combined RNAscope and immunofluorescence staining sections were
processed as for multiplex immunofluorescence staining (as above) after the RNAscope protocol. Slides were imaged using a slide
scanner (AxioScan.Z1, Zeiss) at 40X (for RNAscope) magnification or a Zeiss LSM780 inverted confocal microscope. Images were
processed using Zen Blue (Zeiss) and Fiji image software.
EdU Click-iT Immunofluorescence staining
EdU incorporation into DNA was detected using the Click-iT EdU Alexa Fluor Imaging kit (Invitrogen/Molecular Probes, C10640).
Formalin-fixed paraffin-embedded 5mm sections were dewaxed, rehydrated, then incubated in 4% neutral-buffered formalin for
20 minutes. Sections were washed in 0.1% Triton X-100 in PBS (PBSTX) for 10 minutes followed by heat-mediated antigen retrieval
in pH6 sodium citrate (microwave; 15 minutes), washed for 10 minutes in PBSTX and blocked for 1 hour using protein block
(GeneTex, GTX30963). The Click-iT solution was then made according to manufacturer’s instructions. Slides were incubated in
the EdU cocktail for 30 minutes and rinsed three times in PBS. The azide used was coupled to an Alexa Fluor 647 fluorophore.
Upon completion of the EdU Click-iT reaction, slides were processed as above for multiplex staining. Sections were imaged using
a slide scanner (AxioScan.Z1, Zeiss) at 20X magnification. Images were processed using Zen Blue (Zeiss) and Fiji image software.
Picrosirius Red Staining
Picrosirius red (PSR) staining was performed using 0.1% Direct Red 80 (Sigma) in 1.3% picric acid solution (Sigma, 239801).
Formalin-fixed paraffin-embedded 5mmsectionswere dewaxed, rehydrated, incubated in 0.4%phosphomolybdic acid for 5minutes,
and washed with PBS. Sections were then stained with picosirius red for two hours, before washing twice with agitation for 30 s in
acidified water. Slides were placed in 0.1% Fast Green (ThermoFisher Scientific, F/P025/46) for 30 seconds followed by two 30 sec-
onds washes with agitation in acidified water. Following dehydration (100% ethanol), slides were cleared in xylene and mounted us-
ing DPX. Sections were imaged using a slide scanner (AxioScan.Z1, Zeiss) at 20X magnification.
Image Quantification
Cell counts for zonation of HSC in uninjured liver, Lhx2+ cell expansion, zonation of HSC following acute liver injury, Pdgfrb-BAC-
eGFP reporting efficiency and specificity, and NGFR and Adamtsl2 marker specificity were counted manually from multiple high-
powered images per sample. For zonation in uninjured liver the peri-central and peri-portal regions were defined as areas of positive
Cyp2e1 or E-cadherin staining, respectively. All areas were processed using Zen Blue software to calculate cell count/mm2. In un-
injured liver and following acute liver injury (72 hours post single CCl4) NGFR was used as a marker for PaHSC and Adamtsl2 as a
marker for CaHSC. For quantification of proliferation following acute injury PaHSC were identified as NGFR+/PDGFRb+ cells and
CaHSC as NGFR-/PDGFRb+ cells.
To quantify PSR staining digital morphometric pixel analysis was performed using the Trainable Weka Segmentation (TWS) plugin
(Arganda-Carreras et al., 2017) in Fiji software (Schindelin et al., 2012). Briefly, the TWS plugin was trained to produce a classifier
segmenting images into areas of positive staining, tissue background and white space. The same trained classifier was applied to
all images to produce a percentage area of positive staining for each tissue section.
Quantitative image analysis of PSR staining in rat tissue was performed using Visiopharm v2017.2. The Tissue Find APP was used
to find the tissue regions in the images, before positive expression was categorized as low, medium, or high based on the level of
staining intensity. Percentage areawas calculated by summing the values for low,medium, and high expression, dividing by the value
for staining on the entire tissue area, and multiplying by 100.
Hydroxyproline Assay
Liver samples were dehydrated overnight at 62C, followed by homogenization in water (50mL water/1mg dry tissue weight) using a
bead-based TissueLyser. Total protein was measured using a BCA protein assay (Pierce (Thermo Fisher) BCA Protein Assay Kit;
23227). Homogenates were hydrolyzed overnight in 6 N HCl at 110C. Samples and orthohydroxyproline standards were added
in duplicate to microplate wells and dried. Chloramine T (Sigma; 857319) was added to all wells and the plate was incubated at
room temperature for 30 minutes with shaking. Ehrlich’s Reagent (Fisher; D71-25) was added to all wells and the plate sealed
and incubated at 60C for 40 minutes. Optical density wasmeasured at 560nm onMolecular Devices’ SpectraMAX PLUSMicroplate
Reader. OH-P content was calculated for all samples and normalized to total protein and compared to an 8-point standard curve.
Immunocytochemistry
TWNT4 cells (Nakagawa et al., 2016) (courtesy of Bryan Fuchs, PhD) were plated on 96-well optical plates (Greiner Bio-One;
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(GIBCO; 10378)), serum-starved overnight, was pretreated with DMSO or 1mMLPAR1 antagonist (BMS-986020) (Palmer et al., 2018)
(Medchem Express; HY-100619) for 30minutes, then treated with 0.1%BSA (control) or 10mM18:2 LPA (Avanti Polar Lipids; 857138)
for 20 minutes. Cells were then fixed in 4% paraformaldehyde for 20 minutes at room temperature, washed with PBS, permeabilized
with 0.3% TritionX-100/PBS, blocked with 2% BSA/PBS, and stained with Alexa647-phalloidin, mouse anti-pMLC2 (mAb3675, Cell
Signaling Technology), and Hoechst 33342 (ThermoFisher; H3570). Images were acquired with ImageXpress Pico automated imag-
ing system (Molecular Devices).
Contraction Assay
Collagen gel contraction assay was performed using the CytoSelect 48-Well Cell Contraction Assay Kit (CBA-5021). In brief, TWNT4
cells (200K cells/well) were mixed with collagen solution and allowed to polymerize at 37C in a CO2 incubator for 1 hour. After
collagen gel polymerization, 0.5ml media (Serum free- DMEM, (GIBCO; 15-018-CM)) containing either 3 mM LPAR1 antagonist
(BMS-986020) or DMSOwere added atop the collagen lattice for 30 minutes, followed by addition of 50 mM LPA (Avanti Polar Lipids)
and incubation at 37C and 5% CO2. Media was changed daily by carefully removing 250ml of media and replacing with 250ml (with
/without contractionmediators). Collagen gel contraction wasmeasured after 96 hours using light invertedmicroscopy or on a Celigo
imaging cytometer platform (Nexcelom Biosciences) using the bright-field channel. Contracted gel area was quantified using ImageJ
analysis.
qPCR
Primary HSC or TWNT4 cells were pre-treated for 30minutes with 3mMLPAR1 antagonist (BMS-986020) or DMSO, followed by addi-
tion of 10mM 18:2 LPA (Avanti Polar Lipids) for 2 hours. RNA was isolated using the RNeasy Plus Mini Kit (QIAGEN) and cDNA was
made using the High Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific; 4368814). RT-qPCR for CTGF and HPRT1
was performed using TaqMan Gene Expression Assays (ThermoFisher Scientific, Hs00170014_m1 and Hs02800695_m1).
Primary cell isolation
Digestion protocol 1
Mouse liver was perfused through the inferior vena cava with phosphate buffered saline (PBS). The liver was excised, minced with a
scalpel, digested in 5mg/ml pronase (Sigma, P5147), 2.84mg/ml collagenase B (Roche, 11088815001; 0.188U/mg) and 0.019mg/ml
DNase 1 (Roche, 10104159001) at 37C for 20minuteswith agitation (200–250 rpm), and then strained through a 120mmnybolt mesh.
The cell suspension was centrifuged at 400g for 7 minutes, supernatant removed, cell pellet resuspended in PEB buffer (PBS, 2%
FBS, and 2mM EDTA), and DNase I added (0.02mg/ml). Following red blood cell lysis with RBC lysis buffer (BioLegend;
Cat:420301), the cell suspension was again centrifuged at 400g for 7 minutes, supernatant removed, cell pellet resuspended in
PEB buffer and DNase 1 added (0.02mg/ml).
Digestion protocol 2
Hepatic stellate cells (HSC) were isolated from mice as described previously (Mederacke et al., 2015). Mice were anaesthetized via
inhalation of isoflurane (1%–3%). Following cannulation of the inferior vena cava, the portal vein was cut to allow retrograde stepwise
perfusion of EGTA (0.19mg/ml; 2 minutes), pronase (0.4mg/ml; 5 minutes; Sigma, P5147) and collagenase D (0.185U/ml; 7 minutes;
Roche, 11088882001) containing GBSS/B solutions (Sigma, G9779). Liver was then excised and minced before ex vivo digestion in
GBSS/B (Sigma, G9779) containing 0.5mg/ml pronase, 0.088U/ml collagenase D and 1% DNase 1 (Roche, 10104159001). The re-
sulting cell suspensionwas then strained through a 70mmcell strainer and centrifuged at 580g for 10minutes, before supernatant was
removed and the cells resuspended in GBSS/B containing DNase I. Following a further centrifugation (580g for 10 minutes), HSC
were isolated from the digest solution by Histodenz (Sigma, D2158-100G) gradient centrifugation (1380g for 17 minutes).
Cell sorting
Cells were blocked in 1% purified anti-mouse CD16/32 (BioLegend; Clone. 93 Cat. 101324; Lot. B254979) and 10% normal mouse
serum (Sigma,M5905) for 10minutes at 4C before incubation with antibodies CD45-PE/Cy7 (1:100; BioLegend; Clone: 30-F11; Cat.
103114; Lot. B243728) andCD102-AF647 (1:100; BioLegend; Clone: 3C4 (MIC2/4); Cat. 105612; Lot. B227625) for 20minutes at 4C.
For cells isolated from digestion protocol 1 live/dead (DAPI 1:1000) staining was performed immediately prior to running the samples.
For cells isolated fromdigestion protocol 2 DAPI was replacedwith 7-AAD viability stain (BioLegend; Cat. 420404; Lot. B251165). Cell
sorting was performed on a FACS Aria II (Becton Dickinson, Basel, Switzerland).
Human liver tissue RNA-seq
RNA sequencing was performed by Q2 Solutions (Morrisville, North Carolina). For human liver samples, total RNA was isolated from
three 11mmFFPE curls per sample in one tube (33mm total). All samples had > 100ng of input RNA. Sequencing libraries were created
using the TruSeq RNA Access target enrichment and library preparation methodology which provides high data quality data even
from degraded or FFPE-derived RNA samples. Libraries were sequenced on a Illumina HiSeq2500 with 50bp paired-end sequencing
and a total read depth of 40M reads per sample. R packages edgeR and limma were used to normalize sequence count data ande5 Cell Reports 29, 1832–1847.e1–e8, November 12, 2019
conduct differential gene-expression analysis. False discovery rate (FDR) was calculated using the Benjamini-Hochberg method
(Benjamini and Hochberg, 1995).
Single-cell workflows
10X Chromium
Single cells were processed through the ChromiumTM Single Cell Platform using the ChromiumTM Single Cell 30 Library and Gel Bead
Kit v2 (10XGenomics, PN-120237) and the ChromiumTMSingle Cell A Chip Kit (10XGenomics, PN-120236) as per themanufacturer’s
protocol. In brief, single cells were sorted into PBS + 2% FBS, washed twice and counted using a Bio-Rad TC20. Approxiamtely
10,769 cells were added to each lane of a 10X chip and partitioned into Gel Beads in Emulsion in the ChromiumTM instrument, where
cell lysis and barcoded reverse transcription of RNA occurred, followed by amplification, fragmentation and 50 adaptor and sample
index attachment. Libraries were sequenced on an Illumina HiSeq 4000.
Smart-seq2
Single cells were processed by SciLifeLab – Eukaryotic Single cell Genomic Facility (Karolinska Institute). Before shipping single cells
were sorted into wells of a 384-well plate containing pre-prepared lysis buffer. Libraries were sequenced on an Illumina HiSeq 4000.
Pre-processing scRNA-seq data
Mouse 10X Chromium:
We aligned to themm10 reference genome (Ensembl 84) and estimated cell-containing partitions and associated UMIs using the Cell
Ranger v2.1.0 Single-Cell Software Suite from 10X Genomics. Genes expressed in fewer than three cells in a sample were excluded,
as were cells that expressed fewer than 300 genes or mitochondrial gene content > 30% of the total UMI count. We normalized by
dividing the UMI count per gene by the total UMI count in the corresponding cell and log-transforming. Variation in UMI counts be-
tween cells was regressed according to a negative binomial model, prior to scaling and centering the resulting value by subtracting
the mean expression of each gene and dividing by its standard deviation (En), then calculating ln(10
4*En+1). Highly variable genes
were identified using Seurat’s FindVariableGenes function with default parameters. Non-mesenchymal mouse scRNA-seq data
following chronic CCl4-induced liver fibrosis were analyzed from our previously-obtained datasets (Ramachandran et al., 2019).
Human 10X Chromium:
We aligned to the GRCh38 reference genome (Ensembl 84) and processed our single-cell transcriptomic data as above. Mesen-
chymal cells were isolated based on PDGFRB expression.
Mouse Smart-seq2
The single-cell transcriptomic data was initially processed at the Eukaryotic Single-Cell Genomics Facility at the Science for Life Lab-
oratory in Stockholm, Sweden: obtained reads were mapped in STAR to the mm10 build of the mouse genome (concatenated with
transcripts for eGFP and the ERCC spike-in set), and then processed via rpkmforgenes, MULTo, and RefSeq to yield a count for each
endogenous gene, spike-in, and eGFP transcript per cell. We performed quality control in R packages scater v1.6.3 (McCarthy et al.,
2017) and scran v1.6.9 (Lun et al., 2016), removing cells with library size or features less than, or with ERCCpercentage greater than, 3
median absolute deviations from the dataset median. We then computed normalized expression using sum factors (with separate
calculation of spike-in factors), before transferring these values to Seurat to identify highly variable genes as above.
Dimensionality reduction, clustering, and DE analysis
We performed unsupervised clustering and differential gene expression analyses in the Seurat R package v2.3.0 (Satija et al., 2015).
In particular we used SNN graph-based clustering, where the SNN graph was constructed using from 2 to 10 principal components
as determined by dataset variability shown in principal components analysis (PCA); the resolution parameter to determine the result-
ing number of clusters was also tuned accordingly. In total, we present scRNA-seq data from nine mouse liver samples in 10X (three
uninjured, three acute CCl4, three chronic CCl4) and three mouse liver samples in SmartSeq2 (all uninjured).
All heatmaps, t-SNE visualizations, and violin plots were produced using Seurat functions in conjunction with the ggplot2, pheat-
map, and gridR packages. t-SNE visualizations were constructed using the same number of principal components as the associated
clustering, with perplexity ranging from 100 to 300 according to the number of cells in the dataset. We conducted differential gene
expression analysis in Seurat using an AUC classifier to assess significance, retaining only those genes with a log-fold change of at
least 0.25 and expression in at least 25% of cells in the cluster under comparison.
Defining cell expression signatures
Signature scores were defined per cell as the geometric mean of the expression of the associated signature genes, scaled to a range
of 0 to 1 across the dataset. For a signature of fibrillar collagen production we aggregated expression of the following genes:Col1a1,
Col1a2, Col3a1. For a signature of proliferation we aggregated expression of the following genes: Mki67, Cdca8, Cdc20, Ccna2,
Ccnb1. To perform unbiased thresholding on these scores we used k-means clustering (using the threshold function from themmand
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Identifying and applying an HSC zonation signature
We used unsupervised Independent Component Analysis (ICA) in Seurat to generate components of variability in uninjured HSCs.
Analyzing each component in turn, we identified and isolated the one with highest correlation to observed Ngfr heterogeneity. We
then thresholded on the gene weight loadings along this component of interest to extract an 81-gene signature, including 52 genes
associated with Ngfr and 29 genes associated with Spon2.
Using this 81-gene signature as the input to supervised Seurat clustering, we clustered the homeostatic HSCs into two subpop-
ulations: Ngfrhi and Ngfrlo/neg. We classified acute and chronic CCl4 HSCs into the same two subpopulations in the same manner. To
assess whether the zonation profiles of these signature genes remained consistent across acute and chronic injury, we ordered the
cells at each time point by the strength at which they expressed the 52-gene Ngfr-associated signature and manually inspected the
profile of each gene across this ordering.
Analyzing functional phenotypes of mesenchymal cells
For further analysis of the function related gene expression profile we adopted the self-organizing maps (SOM) approach as imple-
mented in the SCRAT R package v1.0.027. For each lineage of interest we constructed a SOM in SCRAT using default input param-
eters and according to its clusters. We defined the signatures expressed in a cell by applying a threshold criterion (ethresh = 0.95 3
emax) selecting the highest-expressed metagenes in each cell, and identified for further analysis those metagene signatures defining
at least 30% of cells in at least one cluster within the lineage. We smoothed these SOMs using the disaggregate function from the
raster R package for visualization purposes, and scaled radar plots to maximum proportional expression of the signature. Gene
ontology enrichment analysis on the genes in these spots was performed using PANTHER 13.1 (http://pantherdb.org).
Inferring injury dynamics and transcriptional regulation
To generate cellular trajectories (pseudotemporal dynamics) we used the monocle R package v2.6.1 (Trapnell et al., 2014). We or-
dered cells (Ngfrhi versus Ngfrlo/neg) in an unsupervised manner, scaled the resulting pseudotime values from 0 to 1, and mapped
these onto the t-SNE visualizations generated by Seurat. We removed mitochondrial and ribosomal genes from the geneset for
the purposes of trajectory analysis. Differentially-expressed genes along this trajectory were identified using generalized linear
models via the differentialGeneTest function in monocle.
When determining significance for differential gene expression along the trajectory, we set a q-value threshold of 1e-20. We clus-
tered these genes using hierarchical clustering in pheatmap, cutting the tree at k = 3 to obtain gene modules with correlated gene
expression across pseudotime. Cubic smoothing spline curves were fitted to scaled gene expression along this trajectory using
the smooth.spline command from the stats R package, and gene ontology enrichment analysis again performed using PANTHER
13.1.
We verified the trajectory and its directionality using the velocyto R package v0.6.035, estimating cell velocities from their spliced
and unspliced mRNA content. We generated annotated spliced and unspliced reads from the 10X BAM files via the dropEst pipeline,
before calculating gene-relative velocity using kNN pooling with k = 25, determining slope gamma with the entire range of cellular
expression, and fitting gene offsets using spanning reads. Aggregate velocity fields (using Gaussian smoothing on a regular grid)
and transition probabilities per lineage subpopulations were visualized on t-SNE visualizations as generated previously. Gene-spe-
cific phase portraits were plotted by calculating spliced and unspliced mRNA levels against steady-state inferred by a linear model;
levels of unspliced mRNA above and below this steady-state indicate increasing and decreasing expression of said gene, respec-
tively. Similarly we plotted unspliced count signal residual per gene, based on the estimated gamma fit, with positive and negative
residuals indicating expected upregulation and downregulation respectively.
For transcription factor analysis, we obtained a list of all genes identified as acting as transcription factors in humans from Ani-
malTFDB (Zhang et al., 2015). To further analyze transcription factor regulons, we adopted the SCENIC v0.1.7 workflow in R (Aibar
et al., 2017), using default parameters and the normalized data matrices from Seurat as input. For visualization, we mapped the reg-
ulon activity (AUC) scores thus generated to the pseudotemporal trajectories from monocle and the clustering subpopulations from
Seurat.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed using GraphPad Prism (GraphPad Software, USA). Comparison of changes in histological cell
counts, topographical localization of counted cells, morphometric pixel analysis, and gene expressionwere performed using aMann-
Whitney test (unpaired; two-tailed). Comparison of RNA-seq data from human NASH patients was performed using a Kruskal-Wallis
test with Dunn’s multiple comparisons test. Analysis of correlation was performed using a Spearman correlation coefficient. All sta-
tistical tests used, exact value of n, and P values obtained are displayed in the figure legends. P values < 0.05 were considered sta-
tistically significant.e7 Cell Reports 29, 1832–1847.e1–e8, November 12, 2019
DATA AND CODE AVAILABILITY
All mousemesenchymal data is deposited in theGene Expression Omnibus. The accession number for the data is GEO: GSE137720.
All human mesenchymal data, as well as mouse leucocyte data, is available from the Gene Expression Omnibus (GEO: GSE136103).
R markdown scripts enabling the main steps of the analysis are available from the Lead Contact upon reasonable request.
Additional Resources
Our uninjured and 6 week CCl4 expression data is freely available for user-friendly interactive browsing online: http://
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